Ronnda L. Bartel
Keine laufenden Positionen mehr
Profil
Ronnda L.
Bartel held several positions in the science and technology industry.
She was the Executive Director of Biological Research at MicroIslet, Senior Director of Science & Technology at SRS Capital LLC, Senior Principal Scientist of Cell Biology at Advanced Tissue Sciences, and Vice President of Scientific Development at StemCells Inc. She later became the Chief Scientific Officer at Vericel Corp.
from 2010 to 2013.
Bartel received her undergraduate degree from Tabor College and her doctorate from the University of Kansas.
Ehemalige bekannte Positionen von Ronnda L. Bartel
| Unternehmen | Position | Ende |
|---|---|---|
| VERICEL CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2013 |
StemCells, Inc.
 StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Corporate Officer/Principal | - |
MicroIslet, Inc.
 MicroIslet, Inc. Miscellaneous Commercial ServicesCommercial Services MicroIslet, Inc. operates as a biotechnology company, which researches, develops, and commercializes patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The company was founded on August 21, 1998 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
SRS Capital LLC
 SRS Capital LLC Financial ConglomeratesFinance SRS Capital LLC offers investment banking and financial services. It provides advisory services which includes mergers & acquisitions, divestitures, strategic business alliances and direct investing. The company also provides services to the pharmaceutical, healthcare, medical technology and biotechnology fields. SRS Capital was founded by Stanley B. Stein and is headquartered in New York, NY. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Advanced Tissue Sciences, Inc. | Corporate Officer/Principal | - |
Ausbildung von Ronnda L. Bartel
| University of Kansas | Doctorate Degree |
| Tabor College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VERICEL CORPORATION | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| Advanced Tissue Sciences, Inc. | Commercial Services |
SRS Capital LLC
SRS Capital LLC Financial ConglomeratesFinance SRS Capital LLC offers investment banking and financial services. It provides advisory services which includes mergers & acquisitions, divestitures, strategic business alliances and direct investing. The company also provides services to the pharmaceutical, healthcare, medical technology and biotechnology fields. SRS Capital was founded by Stanley B. Stein and is headquartered in New York, NY. | Finance |
MicroIslet, Inc.
MicroIslet, Inc. Miscellaneous Commercial ServicesCommercial Services MicroIslet, Inc. operates as a biotechnology company, which researches, develops, and commercializes patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The company was founded on August 21, 1998 and is headquartered in San Diego, CA. | Commercial Services |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
